Procyrion raises $57.7M Series E for circulatory support device

The Aortix pump therapy device. [Image courtesy of Procyrion]Procyrion announced today that it completed a $57.7 million Series E funding round to support its Aortix device.

Fannin Partners led the round, which included the conversion of $10 million in interim financing. New and existing family/multi-family office investors partnered with Fannin Partners in the financing. Returning investors, including BlueBird Ventures and an undisclosed strategic investor, also participated.

Houston-based Procyrion plans to use the funds to support the ongoing DRAIN-HF pivotal IDE trial evaluating Aortix. The company designed Aortix for percutaneous mechanical circulatory support (pMCS) in patients with acute decompensated heart failure (ADHF) who remain congested despite standard medical therapy (cardiorenal syndrome or CRS). Procyrion enrolled the first patient in the trial in November 2023.

Aortix, a catheter-deployed pump, goes in the descending thoracic aorta. Procyr…

Read more
  • 0

Aortix circulatory support device from Procyrion produces positive study results

The Aortix pump therapy device. [Image courtesy of Procyrion]Procyrion today announced study results demonstrating that use of its Aortix device led to rapid decongestion in a pilot study.

Houston-based Procyrion evaluated Aortix percutaneous mechanical circulatory support (pMCS) pump in patients with acute decompensated heart failure (ADHF) and worsening renal function. This is known as cardiorenal syndrome (CRS).

The pump patients — unresponsive to available medical therapy — demonstrated significant improvements across a range of functions. These include kidney function, cardiac function and patient-reported assessment of shortness of breath at 30 days.

Procyrion presented results today at the Technology and Heart Failure Therapeutics (THT) conference in Boston.

Dr. Jennifer A. Cowger, section head of heart transplantation and mechanical circulatory support, Henry Ford Hospital in Detroit, said patients with CRS often end up the most difficult to …

Read more
  • 0